1. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546: 498-503, 2017.  [Article] 

 doi: 10.1038/nature22341 PMID: 28607485.

 

2. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523: 177-82, 2015.  [Article] 

 doi: 10.1038/nature14581 PMID: 26106858.

 

3. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, Villanueva A, Montoya G, Yamamoto H, Schwartz S, Esteller M

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer cell 18: 303-15, 2010.  [Article] 

 doi: 10.1016/j.ccr.2010.09.007 PMID: 20951941.

 

4. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer cell 26: 707-21, 2014.  [Article] 

 doi: 10.1016/j.ccell.2014.09.005 PMID: 25446899.

 

5. Melo SA, Kalluri R

miR-29b moulds the tumour microenvironment to repress metastasis. Nature cell biology 15: 139-40, 2013.  [Editorial Material] 

 doi: 10.1038/ncb2684 PMID: 23377028.

 

6. Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, Léveillé N, Kalluri R, de Laat W, Agami R

eRNAs are required for p53-dependent enhancer activity and gene transcription. Molecular cell 49: 524-35, 2013.  [Article] 

 doi: 10.1016/j.molcel.2012.11.021 PMID: 23273978.

 

7. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome biology 18: 98, 2017.  [Article] 

 doi: 10.1186/s13059-017-1224-0 PMID: 28535802.

 

8. Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M

The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome research 19: 438-51, 2009.  [Article] 

 doi: 10.1101/gr.083550.108 PMID: 19208682.

 

9. Léveillé N, Melo CA, Rooijers K, Díaz-Lagares A, Melo SA, Korkmaz G, Lopes R, Akbari Moqadam F, Maia AR, Wijchers PJ, Geeven G, den Boer ML, Kalluri R, de Laat W, Esteller M, Agami R

Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nature communications 6: 6520, 2015.  [Article] 

 doi: 10.1038/ncomms7520 PMID: 25813522.

 

10. Baglio SR, Lagerweij T, Pérez-Lanzón M, Ho XD, Léveillé N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi L, Greco M, van Eijndhoven MAJ, Grisendi G, Dominici M, Bonafede R, Lougheed SM, de Gruijl TD, Zini N, Cervo S, Steffan A, Canzonieri V, Martson A, Maasalu K, Köks S, Wurdinger T, Baldini N, Pegtel DM

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression. Clinical cancer research : an official journal of the American Association for Cancer Research 23: 3721-3733, 2017.  [Article] 

 doi: 10.1158/1078-0432.CCR-16-2726 PMID: 28053020.

 

11. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America 108: 4394-9, 2011.  [Article] 

 doi: 10.1073/pnas.1014720108 PMID: 21368194.

 

12. Borges FT, Melo SA, Özdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH, LeBleu VS, Kalluri R

TGF-ß1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. Journal of the American Society of Nephrology : JASN 24: 385-92, 2013.  [Article] 

 doi: 10.1681/ASN.2012101031 PMID: 23274427.

 

13. Melo SA, Esteller M

Disruption of microRNA nuclear transport in human cancer. Seminars in cancer biology 27: 46-51, 2014.  [Review] 

 doi: 10.1016/j.semcancer.2014.02.012 PMID: 24607282.

 

14. Ruivo CF, Adem B, Silva M, Melo SA

The Biology of Cancer Exosomes: Insights and New Perspectives. Cancer research 77: 6480-6488, 2017.  [Review] 

 doi: 10.1158/0008-5472.CAN-17-0994 PMID: 29162616.

 

15. Melo SA, Kalluri R

Angiogenesis is controlled by miR-27b associated with endothelial tip cells. Blood 119: 2439-40, 2012.  [Editorial Material] 

 doi: 10.1182/blood-2012-01-403642 PMID: 22422815.

 

16. Melo SA, Kalluri R

Molecular pathways: microRNAs as cancer therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research 18: 4234-9, 2012.  [Article] 

 doi: 10.1158/1078-0432.CCR-11-2010 PMID: 22711704.

 

17. Melo CA, Léveillé N, Rooijers K, Wijchers PJ, Geeven G, Tal A, Melo SA, de Laat W, Agami R

A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response. Oncogene 35: 4399-406, 2016.  [Article] 

 doi: 10.1038/onc.2015.502 PMID: 26776159.

 

18. Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA, Esteller M

CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29: 6390-401, 2010.  [Article] 

 doi: 10.1038/onc.2010.361 PMID: 20802525.

 

19. Bastos N, Ruivo CF, da Silva S, Melo SA

Exosomes in cancer: Use them or target them? Seminars in cell & developmental biology 78: 13-21, 2018.  [Review] 

 doi: 10.1016/j.semcdb.2017.08.009 PMID: 28803894.

 

20. Barros FM, Carneiro F, Machado JC, Melo SA

Exosomes and Immune Response in Cancer: Friends or Foes? Frontiers in immunology 9: 730, 2018.  [Review] 

 doi: 10.3389/fimmu.2018.00730 PMID: 29696022.

 

21. Melo SA, Esteller M

A precursor microRNA in a cancer cell nucleus: get me out of here! Cell cycle (Georgetown, Tex.) 10: 922-5, 2011.  [Article] 

 PMID: 21346411.

 

22. Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A, Kalluri R

Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. The Journal of biological chemistry 289: 3869-75, 2014.  [Article] 

 doi: 10.1074/jbc.C113.532267 PMID: 24398677.

 

23. Batista IA, Melo SA

Exosomes and the Future of Immunotherapy in Pancreatic Cancer. International journal of molecular sciences 20: ., 2019.  [Review] 

 doi: 10.3390/ijms20030567 PMID: 30699928.

 

24. Melo J, Marques MS, Fernandes T, Fernandes R, Melo SA, Leite M, Figueiredo C

Characterization of Helicobacter pylori outer membrane vesicles and their effect on gastric epithelial cell-cell junctions Helicobacter 23: ., 2018.  [Meeting Abstract] 

.

 

25. Moutinho-Ribeiro P, Melo S, Macedo G

Glypican-1 circulating exosomes: a promising clue to individualize surveillance of pancreatic cysts? European radiology 28: 3018-3019, 2018.  [Article] 

 doi: 10.1007/s00330-018-5321-6 PMID: 29450714.

 

26. Melo SA, Esteller M

Dysregulation of microRNAs in cancer: playing with fire. FEBS letters 585: 2087-99, 2011.  [Review] 

 doi: 10.1016/j.febslet.2010.08.009 PMID: 20708002.

 

27. Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, Melo SA, LeBleu VS, Kalluri R

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer biology & therapy 18: 158-165, 2017.  [Article] 

 doi: 10.1080/15384047.2017.1281499 PMID: 28121262.

 

28. Simó-Riudalbas L, Melo SA, Esteller M

DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Genes, chromosomes & cancer 50: 527-34, 2011.  [Article] 

 doi: 10.1002/gcc.20877 PMID: 21484930.

 

29. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA

The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). International journal of oncology 46: 17-27, 2015.  [Review] 

 doi: 10.3892/ijo.2014.2712 PMID: 25338714.

 

30. Silva M, Melo S

Non-coding RNAs in Exosomes: New Players in Cancer Biology Current genomics 16: 1, 2015.  [Article] 

 doi: 10.2174/1389202916666150707154719 PMID: 27047249.

 

31. Neto SJ, Marques J, Rad R, Melo SA, Machado JC, Costa JL

Horizontal transmission of mutation-driven drug resistance in cancer Medicine 98: ., 2019.  [Meeting Abstract] 

.

 

32. Junqueira-Neto S, Batista IA, Costa JL, Melo SA

Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta cytologica 63: 479-488, 2019.  [Review] 

 doi: 10.1159/000493969 PMID: 30783027.

 

33. Melo CA, Melo SA

MicroRNA biogenesis: dicing assay. Methods in molecular biology (Clifton, N.J.) 1182: 219-26, 2014.  [] 

 doi: 10.1007/978-1-4939-1062-5_20 PMID: 25055915.